PHILADELPHIA - A new treatment procedure for high-grade cancers of the brain, one of the most aggressive and deadliest forms of cancer, has shown promise in extending the survival time of patients participating in a clinical trial conducted under the supervision of Luther W. Brady, M.D., the Hylda Cohn/American Cancer Society Professor of Clinical Oncology at Drexel University College of Medicine. The trial was performed in collaboration with The Wistar Institute in Philadelphia.
The findings, published in the December issue of the American Journal of Clinical Oncology, are the results of the first 10 years of an ongoing study begun in 1987. The study follows 180 patients who, following surgery and radiation therapy for their brain tumors, received injections of MAb425, a radioiodinated monoclonal antibody developed at The Wistar Institute. All of the patients were followed for five years or longer.
"These results clearly indicate a dramatic step forward in the treatment of brain tumors," says Brady.
Typically, patients with lower-grade gliomas, or brain tumors, die within 18 to 24 months, according to Brady. Patients with glioblastomas, a more aggressive form of tumor, usually die within 12 to 18 months. Of the 180 patients receiving the MAb425 injections, three patients with high-grade tumors were alive after five years and longer. Of the patients with the less aggressive tumor, eight were alive after five years and longer, and 50 percent of those patients were alive after 56 months.
"It's gratifying to see an antibody discovered in a Wistar laboratory showing such promise in the clinic against difficult-to-treat brain tumors," says Russel E. Kaufman, M.D., director and CEO of The Wistar Institute. "The process of translating basic discoveries into new therapies is often a lengthy and challenging one, but the reward can be profound - the ability to offer longer, healthier lives to patients."
The scientists who develoPage: 1 2 Related biology news :1
Contact: Franklin Hoke
The Wistar Institute
. Wistar-discovered antibody will help diagnose appendicitis2
. Experimental hantavirus vaccine elicits strong antibody response in primates3
. Towards an AIDS vaccine: unusual antibody that targets HIV described by scientists at TSRI4
. Structure of HIV-neutralizing antibody solved5
. New antibody library speeds search for new detection tools6
. FDA approves new treatment, Campath , humanized monoclonal antibody, for patients with B-cell chronic lymphocytic leukemia7
. Rockefeller University researchers discover immune-cell mechanism that boosts therapeutic antibody potency8
. Abgenix to become sole owner of Xenomouse fully human antibody technology9
. Abgenix and CuraGen establish large-scale drug development alliance, companies to develop genomics-based human antibody drugs10
. Human Genome Sciences and Abgenix enter a broad collaboration to create fully human antibody
. Abgenix and Chiron enter Xenomouse Technology Collaboration, targets antibody products for autoimmune
disease and cancer